Coherus Biosciences | CHRS - Operating Expenses


Coherus Biosciences reported $53.03M in Operating Expenses for its fiscal quarter ending in March of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Akebia Therapeutics USD 43.82M 16.98M Mar/2025
ALKERMES USD 326.44M 1.41B Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amarin USD 51.37M 14.6M Sep/2025
Amgen USD 5.9B 773M Dec/2025
Baxter International USD 3.19B 554.4M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Coherus Biosciences USD 53.03M 43.41M Mar/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Fujifilm JPY 767.39B 27.7B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Merck USD 10.16B 558M Dec/2025
Myriad Genetics USD 229M 3.4M Sep/2025
Pacira USD 193.68M 27.32M Dec/2025
Perrigo USD 1.03B 75.3M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025
Xencor USD 81.86M 13.35M Dec/2025
Zoetis USD 1.55B 3.85B Dec/2025